FDA approves Eli Lilly Alzheimer’s drug, expanding treatment options in the U.S.

[ad_1]

It's a long-awaited win for Eli Lilly after donanemab faced several delays in its path to the market, including an initial rejection from the FDA last year.

[ad_2]

Source link